Fig. 5From: Potential role of epicardial adipose tissue as a biomarker of anthracycline cardiotoxicityBoxplots depicting: a the distributions of subcutaneous adipose tissue and (b) visceral adipose tissue density at the first (CT-t0) and second (CT-t1) computed tomography examination in patients with breast cancer who underwent treatment with anthracyclines, and in controls with no breast cancer who did not undergo cardiotoxic treatment. * denotes statistical significanceBack to article page